913815-82-4

Upstream product

• 70243-51-5 3-endo-hydroxy-9-benzyl-9-azabicyclo[3.3.1]nonane 
• 59741-04-7 2-methoxy-5-methylphenyl isocyanate 
• 363140-31-2 N-(9-benzyl-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate 
• 24566-79-8 2-(6-bromohexyl)isoindole-1,3-dione 
• 371226-28-7 O-(9-azabicyclo[3.3.1]nonan-3α-yl)-N-(2-methoxy-5-methylphenyl)carbamate 
• 1036759-16-6 (2-Methoxy-5-methyl-phenyl)-carbamic acid (1R,3R,5S)-9-[6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-hexyl]-9-aza-bicyclo[3.3.1]non-3-yl ester 

Downstream Products

• 913816-02-1 9-(4-(4'-chlorobenzoylamino)hexyl)-9-azabicyclo[3.3.1]nonan-3α-yl 2-methoxy-5-methylphenylcarbamate 
• 913816-10-1 9-(6-(5-dimethylamino-1-naphthylsulfonylamino)hexyl)-9-azabicyclo[3.3.1]nonan-3α-yl 2-methoxy-5-methylphenylcarbamate 

Relevant academic research and scientific papers

SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC50 value below 5 μΜ against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands

A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs was prepared and their affinities for sigma (σ1 and σ2) receptors were measured in vitro. The results of their structure-activity relationship study ide